World-Pharmacists-Day-Insert
X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Country filter
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Plasma-based therapies

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Large molecule

            Partner/Sponsor/Collaborator: Grifols International

            Deal Size: $146.0 million Upfront Cash: Undisclosed

            Deal Type: Acquisition September 07, 2020

            Details:

            Alkahest currently has four candidates in six phase-2 clinical trials covering therapeutic products for neurodegenerative, cognitive decline, neuromuscular and ophthalmic indications .

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Human iPSC-derived cardiomyocytes

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Curi Bio

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Acquisition July 23, 2020

            Details:

            Through the acquisition, Curi will gain access to Dana’s AI/ML-based platforms including PhenoLearn™, a deep learning platform for modeling cell and tissue phenotypes; Pulse™, an automated platform for contractility analysis of beating cardiomyocytes; and PhenoTox™.